Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Editor

Personal info

View

About

Terms

Javascript disabled

Please enable Javascript support in your browser to use this application.

Instructions on how to enable JavaScript on different browsers can be found here: http://www.google.com/support/bin/answer.py?answer=23852.

[edit this page]

Chemical Compound Review:

Lullan (3aR,7aS)-2-[4-[4-(7-thia-8...

Synonyms: Perospirone, SureCN1155757, ACN-S001249, SM-9018, CCG-100862, ...

This record was replaced with 115368.

Ohno, Y. et al., Ohno, Y. et al., Ishibashi, T. et al., Ohno, Y. et al., Maruoka, Y. et al.

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Lullan

Induction of bradykinesia by SM-9018, a novel 5-HT2 and D2 antagonist, was compared with that of other neuroleptics using the pole test in mice [1].
5. These findings suggest that SM-9018 is weaker than haloperidol in inducing the behavioral dopaminergic hypersensitivity after its chronic treatment and has a lower propensity to cause tardive dyskinesia [2].

Psychiatry related information on Lullan

2. SM-9018 treatment (10 mg/kg/day p.o.) for 2 weeks did not significantly change the density (Bmax) of striatal D2 receptors or the incidence of stereotyped behavior induced by apomorphine (APO) [3].

High impact information on Lullan

These findings suggest that SM-9018 is weaker than haloperidol for induction of striatal c-fos mRNA expression, to which the 5-HT2 receptor blocking activity of SM-9018 seems to contribute [4].
Northern blot analysis was performed to compare the effects of SM-9018 and of haloperidol on the striatal c-fos mRNA expression in rats [4].
4. Neither SM-9018 nor HAL treatment changed the density of 5-HT1A receptors in the hippocampus [3].
3. The density of 5-HT2 receptors in the cerebral cortex was significantly reduced (about 20%) by SM-9018 treatment without being affected by HAL [3].
1. Receptor binding and behavioral studies were performed to compare the effects of subchronic treatments with SM-9018, a novel 5-HT2 and D2 antagonist, and with haloperidol (HAL) on dopamine and 5-HT receptors in rats [3].

Chemical compound and disease context of Lullan

3. The incidence of the apomorphine-induced stereotyped behaviors (e.g., sniffing, chewing, licking and biting) was negligibly affected by SM-9018 treatment, but was markedly enhanced by haloperidol treatment [2].

Biological context of Lullan

5. These findings suggest that SM-9018 is weaker than HAL in inducing up-regulation and supersensitivity of the striatal D2 receptors after the subchronic treatment [3].

Anatomical context of Lullan

These findings suggest that SM-9018, unlike haloperidol, increases DA turnover to a similar extent both in the cerebral cortex and striatum [5].

Gene context of Lullan

Evaluation of bradykinesia induction by SM-9018, a novel 5-HT2 and D2 receptor antagonist, using the mouse pole test [1].

References

Evaluation of bradykinesia induction by SM-9018, a novel 5-HT2 and D2 receptor antagonist, using the mouse pole test. Ohno, Y., Ishida, K., Ikeda, K., Ishibashi, T., Okada, K., Nakamura, M. Pharmacol. Biochem. Behav. (1994) [Pubmed]
Effects of chronic treatments with SM-9018, a potential atypical neuroleptic, on behavioral dopaminergic and serotonergic sensitivities in rats. Ohno, Y., Ishida, K., Ishibashi, T., Ikeda, K., Kato, T., Nakamura, M. Gen. Pharmacol. (1995) [Pubmed]
Effects of subchronic treatments with SM-9018, a novel 5-HT2 and D2 antagonist, on dopamine and 5-HT receptors in rats. Ohno, Y., Ishibashi, T., Okada, K., Ishida, K., Nakamura, M. Prog. Neuropsychopharmacol. Biol. Psychiatry (1995) [Pubmed]
Contrasting effects of SM-9018, a potential atypical antipsychotic, and haloperidol on c-fos mRNA expression in the rat striatum. Ishibashi, T., Ikeda, K., Ishida, K., Yasui, J., Tojima, R., Nakamura, M., Ohno, Y. Eur. J. Pharmacol. (1996) [Pubmed]
Effects of SM-9018, a potential atypical neuroleptic, on the central monoaminergic system in rats. Maruoka, Y., Ohno, Y., Kato, T., Hirose, A., Tatsuno, T., Nakamura, M. Jpn. J. Pharmacol. (1993) [Pubmed]

Contributions to this collaborative article are from individual authors of WikiGenes or mined by the WikiGenes Data Mining Engine from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.About WikiGenes Open Access Licence Privacy Policy Terms of Use apsburg

The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.